Cargando…
The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial
BACKGROUND: Oral tranexamic acid (TXA) has been demonstrated to reduce the blood loss in primary total knee and hip arthroplasty, but the optimal regimen of oral TXA administration is still unknown. This study aimed to find the best number of administrations of oral TXA for primary total knee and hi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539468/ https://www.ncbi.nlm.nih.gov/pubmed/33023637 http://dx.doi.org/10.1186/s13018-020-01983-1 |
_version_ | 1783591060735262720 |
---|---|
author | Ye, Wei Liu, Yafang Liu, Wei Feng Li, Xiao Long Shao, Jianshu |
author_facet | Ye, Wei Liu, Yafang Liu, Wei Feng Li, Xiao Long Shao, Jianshu |
author_sort | Ye, Wei |
collection | PubMed |
description | BACKGROUND: Oral tranexamic acid (TXA) has been demonstrated to reduce the blood loss in primary total knee and hip arthroplasty, but the optimal regimen of oral TXA administration is still unknown. This study aimed to find the best number of administrations of oral TXA for primary total knee and hip arthroplasty. METHODS: The PubMed, Embase, and Cochrane Library databases were searched for relevant studies published before March 20, 2020. Studies clearly reporting a comparison of multiple administrations of oral TXA for total hip/knee replacement were included, and the total blood loss (TBL), intraoperative blood loss (IBL), decline in hemoglobin (DHB), deep vein thrombosis (DVT), intramuscular venous thrombosis (IVT), length of hospital stay (LOS), and transfusion rate were evaluated. The weighted mean differences and relative risks were calculated using a fixed effects or random effects model. RESULTS: Nine studies involving 1678 patients were included in this meta-analysis (TXA 1363 (one administration, 201; two administrations, 496; three administrations, 215; four administrations, 336; five administrations, 115); placebo 315); the results show that compared with placebo groups, oral TXA could significantly reduce the TBL, IBL, DHB, LOS, and transfusion rate. In addition, the incidences of IVT and DVT were similar between the TXA and placebo groups. Moreover, two administrations of oral TXA significantly reduced the TBL and DHB compared with one administration, three administrations of oral TXA were better than two administrations, and four administrations of oral TXA were better than three administrations. CONCLUSION: Our results suggested that oral TXA could significantly reduce the blood loss and the length of hospital stay but could not increase the incidence of DVT and IVT for total joint replacement patients; additionally, the effectiveness of oral TXA administration increased as the number of administrations increased. |
format | Online Article Text |
id | pubmed-7539468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-75394682020-10-08 The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial Ye, Wei Liu, Yafang Liu, Wei Feng Li, Xiao Long Shao, Jianshu J Orthop Surg Res Systematic Review BACKGROUND: Oral tranexamic acid (TXA) has been demonstrated to reduce the blood loss in primary total knee and hip arthroplasty, but the optimal regimen of oral TXA administration is still unknown. This study aimed to find the best number of administrations of oral TXA for primary total knee and hip arthroplasty. METHODS: The PubMed, Embase, and Cochrane Library databases were searched for relevant studies published before March 20, 2020. Studies clearly reporting a comparison of multiple administrations of oral TXA for total hip/knee replacement were included, and the total blood loss (TBL), intraoperative blood loss (IBL), decline in hemoglobin (DHB), deep vein thrombosis (DVT), intramuscular venous thrombosis (IVT), length of hospital stay (LOS), and transfusion rate were evaluated. The weighted mean differences and relative risks were calculated using a fixed effects or random effects model. RESULTS: Nine studies involving 1678 patients were included in this meta-analysis (TXA 1363 (one administration, 201; two administrations, 496; three administrations, 215; four administrations, 336; five administrations, 115); placebo 315); the results show that compared with placebo groups, oral TXA could significantly reduce the TBL, IBL, DHB, LOS, and transfusion rate. In addition, the incidences of IVT and DVT were similar between the TXA and placebo groups. Moreover, two administrations of oral TXA significantly reduced the TBL and DHB compared with one administration, three administrations of oral TXA were better than two administrations, and four administrations of oral TXA were better than three administrations. CONCLUSION: Our results suggested that oral TXA could significantly reduce the blood loss and the length of hospital stay but could not increase the incidence of DVT and IVT for total joint replacement patients; additionally, the effectiveness of oral TXA administration increased as the number of administrations increased. BioMed Central 2020-10-06 /pmc/articles/PMC7539468/ /pubmed/33023637 http://dx.doi.org/10.1186/s13018-020-01983-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Systematic Review Ye, Wei Liu, Yafang Liu, Wei Feng Li, Xiao Long Shao, Jianshu The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial |
title | The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial |
title_full | The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial |
title_fullStr | The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial |
title_full_unstemmed | The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial |
title_short | The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial |
title_sort | optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta-analysis and narrative review of a randomized controlled trial |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539468/ https://www.ncbi.nlm.nih.gov/pubmed/33023637 http://dx.doi.org/10.1186/s13018-020-01983-1 |
work_keys_str_mv | AT yewei theoptimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT liuyafang theoptimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT liuweifeng theoptimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT lixiaolong theoptimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT shaojianshu theoptimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT yewei optimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT liuyafang optimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT liuweifeng optimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT lixiaolong optimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial AT shaojianshu optimalregimenoforaltranexamicacidadministrationforprimarytotalkneehipreplacementametaanalysisandnarrativereviewofarandomizedcontrolledtrial |